Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.41 |
| ▸ | NR2E1 | Q9Y466 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SCN1A | P35498 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31616103 | 1.00 | LMNA (0.55) | LMNACYP1A2KDM4EAGTR1ADRB2 | |
| SCHEMBL31254056 | 1.00 | LMNA (0.55) | LMNACYP1A2KDM4EAGTR1ADRB2 | |
| SCHEMBL764885 | 1.00 | LMNA (0.55) | LMNACYP1A2KDM4EAGTR1ADRB2 | |
| SCHEMBL11303021 | 0.86 | LMNA (0.65) | LMNACYP1A2KDM4EAGTR1ADRB2 | |
| SCHEMBL20379129 | 0.82 | CYP1A2 (0.37) | LMNACYP1A2KDM4EAGTR1ADRB2 | |
| SCHEMBL31616021 | 0.81 | SCN4A (0.47) | LMNACYP1A2KDM4EALOX15ALDH1A1 | |
| SCHEMBL31615918 | 0.81 | SCN4A (0.47) | LMNACYP1A2KDM4EALOX15ALDH1A1 | |
| Butane SCHEMBL14785303 | 0.79 | HTR2C (0.41) | LMNACYP1A2KDM4EAGTR1ALOX15 | |
| Hydrochloric Acid SCHEMBL31616034 | 0.79 | LMNA (0.49) | LMNACYP1A2ALOX15ALDH1A1CYP2D6 | |
| Hydrochloric Acid SCHEMBL31615937 | 0.79 | LMNA (0.49) | LMNACYP1A2ALOX15ALDH1A1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4110878-B1 | WRITING GEL INK FOR PENS WITHOUT FOLLOWER | SOCIéTé BIC (FR) | 2024-03-27 | — | — | EP | claimed |
| EP-3647377-B1 | TEMPERATURE SENSOR INK COMPOSITION WITH METAL OXIDE NANOPARTICLES | XEROX CORP (US) | 2024-01-03 | — | — | EP | claimed |
| EP-2316846-B1 | Spatially-defined macrocyclic compounds useful for drug discovery | OCERA THERAPEUTICS INC (US) | 2019-10-02 | — | — | EP | disclosed |
| US-9181298-B2 | Intermediates for macrocyclic compounds | OCERA THERAPEUTICS, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-8497242-B2 | Processes for intermediates for macrocyclic compounds | TRANZYME PHARMA INC. (CA) | 2013-07-30 | — | — | US | disclosed |
| US-20120226067-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MARSAULT ERIC (CA) | 2012-09-06 | — | — | US | disclosed |
| US-20120226066-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MARSAULT ERIC (CA) | 2012-09-06 | — | — | US | disclosed |
| US-20120226072-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MARSAULT ERIC (CA) | 2012-09-06 | — | — | US | disclosed |
| US-20120165566-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MARSAULT ERIC (CA) | 2012-06-28 | — | — | US | disclosed |
| US-8129561-B2 | Processes for intermediates for macrocyclic compounds | TRANZYME PHARMA INC. (CA) | 2012-03-06 | — | — | US | disclosed |
| US-20110245459-A1 | Processes for Intermediates for Macrocyclic Compounds | IMC EXPLORATION COMPANY | 2011-10-06 | — | — | US | disclosed |
| US-20090137835-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | TRANZYME PHARMA INC. | 2009-05-28 | — | — | US | disclosed |
| US-7452862-B2 | Conformationally-controlled biologically active macrocyclic small molecules as motilin antagonists or ghrelin agonists | TRANZYME PHARMA, INC. (CA) | 2008-11-18 | — | — | US | disclosed |
| EP-1973519-A1 | FORMULATIONS OF LOW OIL CONTENT COMPRISING DIPHENYLMETHANE DERIVATIVES | Symrise GmbH & Co. KG (DE) | 2008-10-01 | — | — | EP | disclosed |
| EP-1807039-A1 | USE OF GLYCOSYLATED FLAVANONES FOR THE BROWNING OF SKIN OR HAIR | Symrise GmbH & Co. KG (DE) | 2007-07-18 | — | — | EP | disclosed |
| WO-2007077260-A1 | FORMULATIONS OF LOW OIL CONTENT COMPRISING DIPHENYLMETHANE DERIVATIVES | SYMRISE GMBH & CO. KG (DE) | 2007-07-12 | — | — | WO | disclosed |
| WO-2006045760-A1 | USE OF GLYCOSYLATED FLAVANONES FOR THE BROWNING OF SKIN OR HAIR | SYMRISE GMBH & CO. KG (DE) | 2006-05-04 | — | — | WO | disclosed |
| EP-0996708-A4 | TRANSGENIC NEMATODE MODEL OF TRIPLET REPEAT NEUROLOGICAL DISEASES | GEN HOSPITAL CORP (US) | 2004-09-08 | — | — | EP | disclosed |
| EP-0996708-A1 | TRANSGENIC NEMATODE MODEL OF TRIPLET REPEAT NEUROLOGICAL DISEASES | THE GENERAL HOSPITAL CORPORATION (US) | 2000-05-03 | — | — | EP | disclosed |
| WO-1999002652-A1 | TRANSGENIC NEMATODE MODEL OF TRIPLET REPEAT NEUROLOGICAL DISEASES | THE GENERAL HOSPITAL CORPORATION (US) | 1999-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137835-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CHRM1 | LMNA 3732/4885CYP1A2 957/4885KDM4E 4765/4885 |
| US-20120165566-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CHRM1 | LMNA 3732/4885CYP1A2 957/4885KDM4E 4765/4885 |
| US-20110245459-A1 | Processes for Intermediates for Macrocyclic Compounds | MLNR, CHRM2, CHRM1 | LMNA 3732/4885CYP1A2 957/4885KDM4E 4765/4885 |
| US-20120226066-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CHRM1 | LMNA 3732/4885CYP1A2 957/4885KDM4E 4765/4885 |
| US-20120226067-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CCKAR | LMNA 3526/4885CYP1A2 942/4885KDM4E 4753/4885 |
| US-20120226072-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CHRM1 | LMNA 3732/4885CYP1A2 957/4885KDM4E 4765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.